This company listing is no longer active
ECX2 Stock Overview
A molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Epigenomics AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €6.40 |
52 Week High | €11.60 |
52 Week Low | €5.92 |
Beta | 1.15 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -37.98% |
Recent News & Updates
Recent updates
Shareholder Returns
ECX2 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 0.6% | -0.5% |
1Y | n/a | -25.7% | 4.3% |
Return vs Industry: Insufficient data to determine how ECX2 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how ECX2 performed against the German Market.
Price Volatility
ECX2 volatility | |
---|---|
ECX2 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ECX2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ECX2's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 36 | Greg Hamilton | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
ECX2 fundamental statistics | |
---|---|
Market cap | €2.56m |
Earnings (TTM) | -€7.25m |
Revenue (TTM) | €567.00k |
4.5x
P/S Ratio-0.4x
P/E RatioIs ECX2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ECX2 income statement (TTM) | |
---|---|
Revenue | €567.00k |
Cost of Revenue | €138.00k |
Gross Profit | €429.00k |
Other Expenses | €7.68m |
Earnings | -€7.25m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Apr 21, 2023
Earnings per share (EPS) | -1.77 |
Gross Margin | 75.66% |
Net Profit Margin | -1,279.54% |
Debt/Equity Ratio | 0% |
How did ECX2 perform over the long term?
See historical performance and comparison